Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.

Awad MM, Forde PM, Girard N, Spicer J, Wang C, Lu S, Mitsudomi T, Felip E, Broderick SR, Swanson SJ, Brahmer J, Kerr K, Saylors GB, Chen KN, Gharpure V, Neely J, Balli D, Hu N, Provencio Pulla M.

Open source

DOI: 10.1200/jco-24-02239
Published: 2025-01-08
Container: J Clin Oncol
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-24-02239,
  title = {Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.},
  author = {Awad MM and  Forde PM and  Girard N and  Spicer J and  Wang C and  Lu S and  Mitsudomi T and  Felip E and  Broderick SR and  Swanson SJ and  Brahmer J and  Kerr K and  Saylors GB and  Chen KN and  Gharpure V and  Neely J and  Balli D and  Hu N and  Provencio Pulla M.},
  year = {2025},
  journal = {J Clin Oncol},
  doi = {10.1200/jco-24-02239},
  url = {https://doi.org/10.1200/jco-24-02239}
}

RIS

TY  - JOUR
TI  - Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
AU  - Awad MM
AU  -  Forde PM
AU  -  Girard N
AU  -  Spicer J
AU  -  Wang C
AU  -  Lu S
AU  -  Mitsudomi T
AU  -  Felip E
AU  -  Broderick SR
AU  -  Swanson SJ
AU  -  Brahmer J
AU  -  Kerr K
AU  -  Saylors GB
AU  -  Chen KN
AU  -  Gharpure V
AU  -  Neely J
AU  -  Balli D
AU  -  Hu N
AU  -  Provencio Pulla M.
PY  - 2025
JO  - J Clin Oncol
DO  - 10.1200/jco-24-02239
UR  - https://doi.org/10.1200/jco-24-02239
ER  -

APA

MM, A., PM, F., N, G., J, S., C, W., S, L., T, M., E, F., SR, B., SJ, S., J, B., K, K., GB, S., KN, C., V, G., J, N., D, B., N, H., & M., P. P. (2025). Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.. J Clin Oncol. https://doi.org/10.1200/jco-24-02239

Source records

europe-pmc · retrieved 2026-09-27T04:57:39.496Z